A Simple Model to Study Tau Pathology.

Area of Science:

• Neuroscience
• Cell Biology
• Biochemistry

Background:

• Tau proteins stabilize microtubules but undergo pathological phosphorylation and aggregation in tauopathies.
• Aberrant tau aggregates are implicated in cellular toxicity, necessitating effective cell models for therapeutic compound screening.

Purpose of the Study:

• To establish and validate a simple, non-neuronal cell model for studying tau phosphorylation and aggregation.
• To investigate the effects of growth factors and inhibitors on intracellular and secreted tau.

Main Methods:

• Overexpression of human tau in a stable human embryonic kidney 293 cell line.
• Monitoring of tau phosphorylation, aggregation, and secretion under specific conditions.
• Assessment of therapeutic compounds, including lithium (a GSK3 inhibitor), for their effects on tau pathology.

Main Results:

• Successfully replicated intracellular tau phosphorylation and aggregation in the engineered cell model.
• Observed changes in secreted tau levels correlating with intracellular tau modifications.
• Demonstrated that lithium effectively reversed tau phosphorylation and aggregation.

Conclusions:

• The human embryonic kidney 293 cell model provides a viable and manageable system for studying tauopathies.
• This model can be utilized to screen for compounds that mitigate tau pathology.
• Targeting GSK3 with inhibitors like lithium shows promise in reversing key pathological features of tau.